Loading
Life sciences · Journal article
Nanomedicine · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Skin cancer is among the most common malignancies worldwide, with a rising global incidence. Cancer develops through complex molecular and genetic changes. Current treatments, such as surgery, chemotherapy, targeted therapy, radiation, and immunotherapy, offer hope. However, challenges like immune evasion, drug resistance, and systemic toxicities prevent long-term success. Nanotechnology-based delivery systems may offer a potential solution to these challenges. Cross-linked polymeric nanogel networks are unique nanocarriers with high drug-loading capacity, biocompatibility, stimuli-responsive release, and enhanced dermal/transdermal penetration. Preclinical studies have investigated nanogels as delivery platforms for chemotherapeutics, phytochemicals, and immunomodulators, with reported improvements in drug loading, controlled release, dermal penetration, and antitumor activity. However, the available evidence remains predominantly preclinical, and further investigation is needed to determine the clinical efficacy and safety of nanogel-based approaches in skin cancer. This review explains the molecular pathology of skin cancer, the advances and limitations of immunotherapy, and the emerging role of nanogels in cancer treatment. It highlights nanogels as a versatile platform for improving dermal and transdermal drug delivery and as a promising approach for enhancing skin cancer treatment. Further well-designed clinical studies are required to bring nanogel-based delivery system from bench to bed-side.